The effect of obesity on regadenoson-induced myocardial hyperemia: A quantitative magnetic resonance imaging study

International Journal of Cardiovascular Imaging

Volumn 28, Issue 6, 2012, Pages 1435-1444

  Di Bella, Edward V R ^a,b   Fluckiger, Jacob U ^a,b   Chen, Liyong ^a,b   Kim, Tae Ho ^c   Pack, Nathan A ^a,b   Matthews, Brian ^a   Adluru, Ganesh ^a   Priester, Tiffany ^d   Kuppahally, Suman ^d   Jiji, Ronny ^d   McGann, Chris ^a,d   Litwin, Sheldon E ^a,d,e,f  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b University of Utah   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF UTAH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Adenosine; Coronary; Magnetic resonance imaging; Myocardial perfusion; Obesity; Regadenoson; Vasodilator

Indexed keywords

ADENOSINE; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; RAPIDSCAN; REGADENOSON; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORONARY HYPEREMIA; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART HEMODYNAMICS; HEART MUSCLE BLOOD FLOW; HEART RATE; HUMAN; MALE; MYOCARDIAL PERFUSION RESERVE; OBESITY; PERFUSION WEIGHTED IMAGING; PHARMACOLOGIC STRESS TESTING; QUANTITATIVE STUDY; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; UNSPECIFIED SIDE EFFECT; UP SLOPE MYOCARDIAL TIME INTENSITY CURVE;

ADENOSINE; ADENOSINE A2 RECEPTOR ANTAGONISTS; ADULT; BODY MASS INDEX; CONTRAST MEDIA; CORONARY CIRCULATION; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; HYPEREMIA; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MAGNETIC RESONANCE IMAGING, CINE; MALE; MEGLUMINE; MIDDLE AGED; MYOCARDIAL PERFUSION IMAGING; OBESITY; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; PURINES; PYRAZOLES; TIME FACTORS; UTAH; VASODILATOR AGENTS;

EID: 84870403373     PISSN: 15695794     EISSN: 15730743     Source Type: Journal    
DOI: 10.1007/s10554-011-9949-4     Document Type: Article

References (31)

1. Poirier P, Giles TD, Bray GA, Hong Y, Stern JS, Pi-Sunyer FX, Eckel RH (2006) Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation 113:898-918
2. Madala MC, Franklin BA, Chen AY, Berman AD, Roe MT, Peterson ED, Ohman EM, Smith SC Jr, Gibler WB, McCullough PA (2008) Obesity and age of first non-stsegment elevation myocardial infarction. J Am Coll Cardiol 52:979-985
3. Al Jaroudi W, Iskandrian AE (2009) Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 54:1123-1130
4. Gordi T, Blackburn B, Lieu H (2007) Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 47:825-833
5. Gordi T, Frohna P, Sun HL, Wolff A, Belardinelli L, Lieu H (2006) A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers. Clin Pharmacokinet 45: 1201-1212 (Pubitemid 44904823)
6. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, Iskandrian AE (2009) Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 157:771-776
7. Booker OJ, Bandettini P, Kellman P, Wilson J, Leung S, Vasu S, Shanbhag S, Henry J, Lowrey T, Mancini C, Arai AE (2011) Time resolved measure of coronary sinus flow following regadenoson administration. J Cardiovasc Magn Reson 13(Suppl 1):O74
8. Watkins S, McGeoch R, Lyne J, Steedman T, Good R, McLaughlin MJ, Cunningham T, Bezlyak V, Ford I, Dargie HJ, Oldroyd KG (2009) Validation of magnetic resonance myocardial perfusion imaging with fractional flow reserve for the detection of significant coronary heart disease. Circulation 120:2207-2213
9. Schwitter J, Wacker CM, van Rossum AC, Lombardi M, Al-Saadi N, Ahlstrom H, Dill T, Larsson HB, Flamm SD, Marquardt M, Johansson L (2008) MR-IMPACT: Comparison of perfusion-cardiac magnetic resonance with single-photon emission computed tomography for the detection of coronary artery disease in a multicentre, multivendor, randomized trial. Eur Heart J 29:480-489 (Pubitemid 351264187)
10. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE (2008) Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging integrated ADVANCE-MPI trial results. JACC Cardiovasc Imaging 1:307-316 (Pubitemid 351676842)
11. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, Lieu H, Mahmarian JJ, Olmsted A, Underwood SR, Vitola J, Wang W (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nucl Cardiol 14:645-658 (Pubitemid 47355078)
12. Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D, Mathur V (2008) Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (regcopd trial). J Nucl Cardiol 15:319-328
13. Leaker BR, O'Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, Lieu HD (2008) Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: a randomized, double-blind, placebo-controlled trial. J Nucl Cardiol 15:329-336
14. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, Shryock J, Belardinelli L, Hintze TH (2007) Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (cvt-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 49:369-375 (Pubitemid 47000311)
15. Kholmovski EG, DiBella EVR (2007) Perfusion MRI with radial acquisition for arterial input function assessment. Magn Reson Med 57:821-827 (Pubitemid 46709401)
16. Adluru G, McGann C, Speier P, Kholmovski EG, Shaaban A, DiBella EV (2009) Acquisition and reconstruction of undersampled radial data for myocardial perfusion magnetic resonance imaging. J Magn Reson Imaging 29: 466-473
17. Kim TH, Pack NA, Chen L, DiBella EVR (2010) Quantification of myocardial perfusion using cmr with a radial data acquisition: comparison with a dual-bolus method. J Cardiovasc Magn Reson 12:45
18. Pack N, Vijayakumar S, Kim TH, McGann C, DiBella E (2009) A semi-automatic software package for analysis of dynamic contrast-enhanced MRI myocardial perfusion studies. Comput Cardiol 36:269-272. http://www.cinc.mit. edu/archives/2009/pdf/0269.pdf
19. Ishimori ML, Martin R, Berman DS, Goykhman P, Shaw LJ, Shufelt C, Slomka PJ, Thomson LE, Schapira J, Yang Y, Wallace DJ, Weisman MH, Bairey Merz CN (2011) Myocardial ischemia in the absence of obstructive coronary artery disease in systemic lupus erythematosus. JACC Cardiovasc Imaging 4:27-33
20. Pack N, DiBella EVR (2010) Comparison of myocardial blood flow estimates from dynamic contrast-enhanced magnetic resonance imaging with four quantitative analysis methods. Magn Reson Med 64:125-137
21. Czernin J, Muller P, Chan S, Brunken RC, Porenta G, Krivokapich J, Chen K, Chan A, Phelps ME, Schelbert HR (1993) Influence of age and hemodynamics on myocardial blood flow and flow reserve. Circulation 88:62-69 (Pubitemid 23195433)
22. Reyes E, Staehr P, Olmsted A, Zeng D, Blackburn B, Cerqueira MD, Underwood SR (2011) Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. J Nucl Cardiol 18:620-627
23. Schindler TH, Cardenas J, Prior JO, Facta AD, Kreissl MC, Zhang XL, Sayre J, Dahlbom M, Licinio J, Schelbert HR (2006) Relationship between increasing body weight, insulin resistance, inflammation, adipocytokine leptin, and coronary circulatory function. JAmColl Cardiol 47:1188-1195
24. Iskandrian AE (1998) State of the art for pharmacologic stress imaging. In: Zaret BL, Beller GA (eds) Nuclear cardiology: state of the art and future directions. Mosby-Year Book, New York, pp 312-330
25. Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG (1999) Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with (15)O-labeled water and PET. J Nucl Med 40: 1848-1856 (Pubitemid 29523579)
26. Elkington AG, Gatehouse PD, Ablitt NA, Yang G-Z, Firmin DN, Pennell DJ (2005) Interstudy reproducibility of quantitative perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 7:815-822 (Pubitemid 41770060)
27. Jerosch-Herold M, Vazquez G, Wang L, Jacobs DR Jr, Folsom AR (2008) Variability of myocardial blood flow measurements by magnetic resonance imaging in the multiethnic study of atherosclerosis. Invest Radiol 43:155-161 (Pubitemid 351643141)
28. Fritz-Hansen T, Hove JD, Kofoed KF, Kelbaek H, Larsson HB (2008) Quantification of MRI measured myocardial perfusion reserve in healthy humans: a comparison with positron emission tomography. J Magn Reson Imaging 27:818-824 (Pubitemid 351508097)
29. Goudarzi B, Fukushima K, Bravo P, Merrill J, Bengel FM (2011) Comparison of the myocardial blood flow response to regadenoson and dipyridamole: a quantitative analysis in patients referred for clinical (82)Rb myocardial perfusion PET. Eur J Nucl Med Mol Imaging 38:1908-1916
30. Giang TH, Nanz D, Coulden R, Friedrich M, Graves M, Al-Saadi N, Luscher TF, von Schulthess GK, Schwitter J (2004) Detection of coronary artery disease by magnetic resonance myocardial perfusion imaging with various contrast medium doses: first European multi-centre experience. Eur Heart J 25:1657-1665 (Pubitemid 39209287)
31. Cury RC, Cattani CA, Gabure LA, Racy DJ, de Gois JM, Siebert U, Lima SS, Brady TJ (2006) Diagnostic performance of stress perfusion and delayed-enhancement mr imaging in patients with coronary artery disease. Radiology 240:39-45 (Pubitemid 43902593)